Nasal Potential Difference in Congenital Bilateral Absence of the Vas Deferens
- 1 September 1998
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 158 (3) , 896-901
- https://doi.org/10.1164/ajrccm.158.3.9711029
Abstract
Congenital bilateral absence of the vas deferens (CBAVD) is supposed to be due to defective activity of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) in the genital tract. With the aim of studying CFTR activity in vivo we measured nasal potential difference (NPD) in a group of CBAVD subjects, who were then compared with normal control subjects and CF patients. Sodium transport, measured under basal conditions and after amiloride superinfusion, was normal in almost all CBAVD patients, who had NPD values similar to those of normal control subjects. Chloride transport was studied by measuring NPD during perfusion with a chloride-free solution and isoproterenol. Under these circumstances CBAVD patients as a whole showed normal chloride secretion. However, three subjects with CBAVD had abnormal NPD values. They had either elevated sweat chloride concentrations together with symptoms of mild CF, or compound heterozygosity (DeltaF508/R117H). In conclusion the group of CBAVD patients as a whole presented normal bioelectric properties of nasal epithelium, suggesting normal CFTR activity. In a small subgroup NPD was abnormal, suggesting a diagnosis of CF, later confirmed by elevated sweat chloride concentrations or positive DNA testing. We suggest that CBAVD patients with altered NPD should undergo further clinical follow-up in order to detect possible late complications of CF.Keywords
This publication has 23 references indexed in Scilit:
- Conventional and modified nasal potential-difference measurement in cystic fibrosis.American Journal of Respiratory and Critical Care Medicine, 1997
- Nasal potential difference in cystic fibrosis patients presenting borderline sweat testEuropean Respiratory Journal, 1997
- Congenital bilateral absence of the vas deferens (CBAVD) and cystic fibrosis transmembrane regulator (CFTR): correlation between genotype and phenotypeHuman Genetics, 1996
- A Controlled Study of Adenoviral-Vector–Mediated Gene Transfer in the Nasal Epithelium of Patients with Cystic FibrosisNew England Journal of Medicine, 1995
- In Vivo Nasal Potential Difference: Techniques and Protocols for Assessing Efficacy of Gene Transfer in Cystic FibrosisHuman Gene Therapy, 1995
- Human airway ion transport. Part two.American Journal of Respiratory and Critical Care Medicine, 1994
- Nasal application of the cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growthEuropean Respiratory Journal, 1994
- Cystic Fibrosis Gene Therapy Using an Adenovirus Vector: In Vivo Safety and Efficacy in Nasal Epithelium. Howard Hughes Medical Institute, Iowa City, IAHuman Gene Therapy, 1994
- Congenital Bilateral Absence of the Vas DeferensJAMA, 1992
- Clinical application of transepithelial potential difference measurements in cystic fibrosisThe Journal of Pediatrics, 1987